Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

Mountain Valley MD $MVMD $MVDMF to Include Testing of South African Mutation in Upcoming COVID-19 BSL-4 Clearance Work $CTLT $MRNA $NVAX

Posted by AGORACOM at 9:29 AM on Monday, February 22nd, 2021
  • Testing South African COVID-19 variant with the Company’s new solubilized Ivermectin technology.
  • Mutation is now the most dominant form of the COVID-19 virus in South Africa

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that it will be testing the new B.1.351 South African COVID-19 variant in its upcoming Bio Safety Level 4 (“BSL-4”) lab study, which is analyzing viral clearance efficacy with the Company’s new solubilized Ivermectin technology.

According to the World Health Organization*, the mutated B.1.351 COVID-19 variant is now the most dominant form of the COVID-19 virus in South Africa and is believed to be more infectious and thus easier to spread. As the COVID-19 virus continually mutates, researchers are assessing the impact of the current vaccines that are in distribution to understand if they may be rendered less effective or even noneffective**.

“We felt it was critical to look at this new South African COVID-19 variant given the immediate complexities we are seeing with the pace of vaccine rollout and the high probability that current vaccines will not be as effective, if at all, against these emerging mutations,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “It is important to us across our broad human health objectives that our solubilized Ivermectin technology can be confidently applied as the broadest COVID-19 therapeutic and number one choice in the world when a vaccine falls short.”

The Company has previously communicated that it believes its solubilized Ivermectin would be suitable for a broad therapeutic across a wide range of viruses in the future, not just limited to COVID-19.

“It is not clear if the current vaccines will protect you from the new variants and early information is that vaccines are not as effective on the mutations. We are attempting in our work with the BSL-4 lab to target novel COVID-19 variants that would prove Ivermectin’s broad activity in interfering with the replication of the virus and thus broadly applies across multiple variants versus being specific to a variant the way a vaccine would be,” stated Mike Farber, Director of Life Sciences at MVMD.

As communicated in the Company’s news release on January 27, 2021, the BSL-4 trial will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/755796-mountain-valley-md-to-include-testing-of-south-african-mutation-in-upcoming-covid-19-bsl-4-clearance-work/messages/2304707#message

St-Georges Eco-Mining $SX $SXOOF Reports on Initial Battery Recovery Test Results $NNX.ca $OM.ca $ICM.ca $ATAO

Posted by AGORACOM at 9:14 AM on Monday, February 22nd, 2021
  • Initial tests on lithium-ion batteries successful in the recovery of lithium, nickel and cobalt found as a coating on aluminium foil in the core of the batteries.
  • Leached more than 99% of the cobalt and of the nickel contained in the batteries.

St-Georges Eco-Mining Corp. (CSE:SX) (OTC:SXOOF) (FSE: 85G1) (CNSX:SX.CN) is pleased to disclose that its initial tests conducted on an array of lithium-ion batteries have been successful in confirming that the selective leach, conducted with its proprietary blend of acids, allows for the recovery of the lithium, nickel and cobalt that are found as a coating on aluminium foil in the core of the batteries.

The Company’s metallurgical team was able to leach more than 99% of the cobalt and of the nickel contained in the batteries. Furthermore, the aluminium foil used to hold the different metals in the batteries’ core remains intact and can be recycled.  

Company scientists are comfortable that the results obtained on these metals are repeatable and should scale. Initial lithium test results have been in line with expectations and require additional tests at scale prior to disclosure. These additional tests are ongoing, and results are expected sometime in March.

Fig. 1 The metals in solution, to the left the lithium / cobalt circuit, to the right the nickel copper circuit.

For testing, batteries were dismantled at the Company’s contracted pilot plant facility, CIMMS, under the supervision of qualified chemists and metallurgists. Enrico Di Cesare, St-Georges VP Research & Development, established the protocol and supervised the process. The batteries were dismantled manually, and the cores were immersed in St-Georges’ proprietary leach solution for 30 minutes. The Company expects to optimize and reduce this exposure duration with the aim of bringing it closer to the 5 min leach time required by the Nevada clays. Aluminium was taken out of the solution in its solid form and set aside. No test for residues was conducted on the aluminium in the preliminary tests. Metals were then targeted for recuperation in solution. The powders obtained were tested on-site and sent for independent testing by CIMMS

Read More: https://agoracom.com/ir/St-GeorgesEco-Mining/forums/discussion/topics/755797-st-georges-reports-on-initial-battery-recovery-test-results/messages/2304710#message

Candente Copper $DNT Corporate Update and Engineering Study Proposals Under Evaluation For Canariaco Copper Deposit $CDG.ca $FCX.ca $TECK.ca $FSUGY $PER.ca

Posted by AGORACOM at 9:01 AM on Monday, February 22nd, 2021
http://blog.agoracom.com/wp-content/uploads/2020/08/candente-copper-for-blog1.jpg
  • Engineering studies to identify and define various value add options for the development of the Cañariaco Project.
  • First goal is to define/identify a smaller, higher grade, start up option for Cañariaco with a smaller CapEx and accelerated payback period

Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper”, “Company”) is pleased to announce that it has received and is reviewing proposals from two internationally acclaimed engineering firms for engineering studies to identify and define various value add options for the development of the Cañariaco Project.

The first goal of the engineering study is to define/identify a smaller, higher grade, start up option for Cañariaco with a smaller initial capital expenditure (“CapEx”) and accelerated payback period. This is expected to be able to be permitted and financed to production more quickly than the larger option. The intention would be that once the development capital is paid back, the smaller operation could then be expanded to fully recognize the value of the large copper-gold resource that exists at Cañariaco.

The second goal is to explore other potential options with a mind to establish both cost efficiencies and environmental, social and governance (“ESG”) friendly development options. Current industry wide ESG initiatives and responsible investing is driving innovation in environmentally friendly, sustainable development and finance products. This innovation has been accelerated by the COVID-19 pandemic and increased urgency around the 17 UN Sustainable Development Goals, resulting in many new development options to consider now.

Read More: https://agoracom.com/ir/CandenteCopper/forums/discussion/topics/755788-corporate-update-and-engineering-study-proposals-under-evaluation/messages/2304699#message

American Creek $AMK “Breaking The Sound Barrier” John Newell and Mining Stock Watch $TUD.ca $ESK.ca $SEA.ca $STNG.ca

Posted by AGORACOM at 8:41 AM on Monday, February 22nd, 2021
  • “Can you see the power it could have when/if it breaks above .40 cents…remember when it broke .10 cents with conviction BOOM!” John Newell, Feb 16, 2021
  • American Creek Resources [TSXV:AMK] has been highlighted by MiningStockWatch.com as 1 of 2 listed “opportunities” on their site.

Sector Expert: John Newell

John Newell is a portfolio manager at Fieldhouse Capital Management and president and CEO of Golden Sky Minerals Corp. He has 38 years of experience in the investment industry acting as an officer, director, portfolio manager and investment advisor with some of the largest investment firms in Canada including Scotia McLeod, CIBC Wood Gundy and Richardson Greenshields (RBC Capital Markets). Newell is a specialist in precious metal equities and related commodities, and follows a disciplined proprietary approach incorporating equity research, analytical frameworks and risk controls to evaluate and select long and short stocks primarily from the Canadian small and mid-cap coverage. Many large, midcap and junior precious metal companies use his technical charts. Newell is a registered portfolio manager in Canada (advising representative).
 
Last week, sector expert John Newell put out a chart showing a possible “Sonic Boom” (as he puts it) in AMK stock similar to what the company experienced when it crossed the 10 cent threshold last year. 

He has updated the charts which are found below.

https://mcusercontent.com/af629dcbbf88a5932a7e484e3/images/a2bafd01-d146-4e4b-bb33-53ad57f849dd.png

American Creek Resources [TSXV:AMK] has been highlighted by MiningStockWatch.com as 1 of 2 listed “opportunities” on their site. To view the site click here.

The website is headed by John Newell and its mission is as follows:

To identify highly profitable trading and investment ideas in the precious metals, industrial metals, and strategic metals space, to help investors position themselves in a metals bull market that we believe has years of great returns ahead of itself.

While no small feat, we look for selected individual companies in this space that we feel the market has overlooked for whatever reasons and believe they will produce out sized returns, over a reasonable time frame. We believe this because our past ideas suggest it is possible. Starting in 2016 we uncovered, Teranga, Alacer, Atlantic Gold, Aurico, Lakeshore, Auryn, Claude, Dalradian, Integra, Kirkland Lake, Klondex, Newmarket, NovaGold, Premier Gold, Richmont, Equinox, Lundin Gold, Great Bear, Tudor, Imperial Metals and Westdome, to name a few. We did this at times when the timing was seemed unlikely or contrarian. We also had some ones that have not worked out yet, McEwen Mining, Almaden, Oceana Gold, because this is not a market sector that you do not experience some disappointment, or the investment time frame is pushed out a few years.

XPhyto Therapeutics $XPHY.ca $XPHYF Builds Commercial Team to Launch 25-Minute Covid-19 Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:32 AM on Monday, February 22nd, 2021
  • Expedited formation of commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system
  • Expects medical device manufacturer approval by the end of February
  • European regulatory approval as a commercial in vitro diagnostic device by early March.

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that the Company has expedited the formation of an experienced commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March.

The market launch team consists of world-class clinical and pharmaceutical executives and service providers who bring the experience and expertise necessary to effectively and rapidly drive the commercialization of Covid-ID Lab. Collectively, the team brings decades of experience in the biotech and pharmaceutical industries, including: executive leadership, business development, regulatory compliance, product launch, international marketing and sales, production, quality assurance, and M&A. In particular, members of the team have led medical diagnostic company growth from inception to over 500 million Euro per year in multinational sales.

“We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization. The team has extensive experience from regulatory approval to international production and sales,” said Hugh Rogers, CEO and Director of XPhyto. “As we near expected regulatory approval, XPhyto’s business is rapidly evolving from innovation to impact. We are working hard to put the Company in the best possible position to execute on our business strategy.”

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/755782-xphyto-builds-commercial-team-to-launch-25-minute-covid-19-rt-pcr-test/messages/2304693#message

VIDEO – Valeo Pharma $VPH $VPHIF Hesperco Capsules at Core of Montreal Heart Institute’s Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 7:38 PM on Sunday, February 21st, 2021
Valeo Pharma (@valeo_pharma) | Twitter

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF is Using Proprietary Tech to Improve Surgery Success Rates and Seize a $5bn Market Opportunity

Posted by AGORACOM-JC at 7:17 PM on Sunday, February 21st, 2021

ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.

  • This includes Wound Healing, Cartilage repair and Osteo-arthritis

So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:

Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):

  • 4m patients in the U.S. alone
  • 600,000 annual surgeries in the U.S. alone
  • $600m+ market opportunity

Meniscus Tear Repair (which is painful and compromises knee function):

  • There are 1.2m surgeries annually in U.S. alone
  • $1bn+ market opportunity

Cartilage Lesions Repair (this is where lesions cause friction and pain):

  • 1.2m detected lesions annually in U.S. alone
  • 120,000 surgeries and a lack of options
  • $1bn+ market opportunity

Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.

@Novamind_Inc $NM.ca $NVMDF Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:54 AM on Saturday, February 20th, 2021

A weekly summary of Novamind news and media

FEATURES February 19, 2021

Dr. Reid Robison on Our Purpose-Driven Mission to Help People who are Suffering

Agoracom interviewed our Chief Medical Officer about our latest expansions, the striking results from treatments, and what it takes to build infrastructure for psychedelic-assisted healthcare.

FEATURES February 18, 2021

Novamind Leading the Charge to Deliver Mental Health Alternatives

Psychedelic Invest published an article about the urgent need for innovative mental health treatments, and the companies working to meet that need.

View all media

Novamind Announces Symbol Change on OTC Market To “NVMDF”

February 19, 2021

View all press releases

Follow @novamind_inc on Instagram

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca

VIDEO – Universal PropTech $UPI Secures Investment and Rights To Finger Scan Test Designed To Detect COVID-19 In Less Than A Minute $AAT.ca $LPS.ca $EGT.ca

Posted by AGORACOM-JC at 6:04 PM on Thursday, February 18th, 2021

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada. 

More than just lip service, UPI clients include:

· Federal Government facilities for over 40 years 

· Manulife 

· Brookfield 

· Billy Bishop Airport 

· University of Toronto 

· …. and many more 

As a result, UPI has generated $35,000,000+ in revenue over the past 3 year – a number most small cap companies would be very happy with.  But newly appointed Chief Growth Officer, Frank Carnevale sees a much bigger opportunity by winning exclusive licenses and partnerships with providers of great products that can significantly grow company revenues … and he has delivered pretty strongly against this mission statement in 2021. 

BUT TODAY HE TOOK A GIANT LEAP FORWARD 

The press release headline says it all:

Universal PropTech Inc. Invests in and Secures defined Agency Rights for ISBRG Corp.’s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute  

In short, this technology takes a non-invasive scan of a person’s finger with a harmless beam of light designed to provide confirmation of Covid-19 infection in less than 1 minute.  

How significant is this announcement and what does it mean to the Company’s growth? 

Watch our interview with CGO Carnevale to learn all about it. 

Harborside Inc. $HBOR $HBORF Announces Closing of Upsized Private Placement For Gross Proceeds of C$35,103,045 $VFF.ca $HARV.ca $ACB.ca

Posted by AGORACOM at 3:56 PM on Thursday, February 18th, 2021

Harborside Inc. (“Harborside”, or the “Company) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, is pleased to announce that it has closed its previously announced upsized brokered private placement of units of the Company at a price of C$2.55 per SVS Unit (as defined below) and C$255.00 per MVS Unit (as defined below) for aggregate gross proceeds of C$35,103,045 (the “Offering”). Beacon Securities Limited and ATB Capital Markets acted as co-lead agents in connection with the Offering (the “Agents”).

“We are very pleased with the strong investor interest and demand we received during our recent upsized offering,” said Peter Bilodeau, Interim CEO of Harborside. “With a strengthened balance sheet, Harborside is well positioned to further accelerate our growth as we enter 2021. We remain focused on continuing to build scale in the California market by optimizing and generating further efficiencies at our Salinas farm while continuing to provide best-in-class retail experiences and the high-quality cannabis products our customers in California have come to expect from Harborside.”

Each unit issued to non-residents of the United States (an “SVS Unit”) is comprised of one subordinate voting share of the Company (a “Subordinate Voting Share”) and one Subordinate Voting Share purchase warrant (a “Warrant”) of the Company. Each Warrant underlying an SVS Unit is exercisable to acquire one Subordinate Voting Share of the Company for a period of 36 months following closing of the Offering (the “Closing”) at an exercise price of C$3.69 per Subordinate Voting Share, subject to adjustment and acceleration in certain events. A total of 5,806,700 SVS Units were issued pursuant to the Offering.

All investors that are considered residents of the United States under the United States Securities Exchange Act of 1934 were issued units (each, an “MVS Unit”) comprised of multiple voting shares of the Company (the “Multiple Voting Shares”) and Multiple Voting Share purchase warrants of the Company, based on the same economic equivalency of each Multiple Voting Share converting into 100 Subordinate Voting Shares. The Multiple Voting Shares are intended to minimize the proportion of the outstanding voting securities of the Company that are held by residents of the United States for purposes of determining whether the Company is a “foreign private issuer”. The holders of Multiple Voting Shares are entitled to one vote in respect of each Subordinate Voting Share into which such Multiple Voting Share could be converted, and as such the Multiple Voting Shares do not necessarily hold voting rights that are superior to the holders of Subordinate Voting Shares, on an as converted to Subordinate Voting Shares basis.  A total of 79,592 MVS Units were issued pursuant to the Offering.

In consideration for their services, the Company paid the Agents a cash commission equal to C$1,451,340.75 and issued the Agents an aggregate of 569,154 broker warrants (“Broker Warrants”). Each Broker Warrant is exercisable to acquire, within 12 months from Closing, one SVS Unit at an exercise price of C$2.55 per SVS Unit.

Read More: https://agoracom.com/ir/HarborsideInc/forums/discussion/topics/755620-harborside-inc-announces-closing-of-upsized-private-placement-for-gross-proceeds-of-c-35-103-045/messages/2304273#message